戻る Agenda
Session 4: Brexit - the Use of MHRA System and Requirements
Session Chair(s)
Merete Joergensen, MBA, MSc
Clinical Disclosure and Transparency Expert, Former EFPIA, CREG Clinical Trials
Merete-J Consulting CVR: 34920818, Denmark
The UK has been on the forefront of transparency requirements. When the UK leaves EU after Brexit, this will have some consequences for the transparency requirements. Objectives: At the conclusion of this session, participants will be able to: • Prepare their organisation to meet the transparency requirements in the UK post Brexit • Know the standpoint from MHRA on requirements and which register to use • Prepare their organisation for the fulfilment of the transparency requirements as monitored by the UK industry association ABPI.
Speaker(s)
Transparency in the U.K. & Brexit
Sheuli Porkess, MD, MRCP, FFPM
The Association of the British Pharmaceutical Industry (ABPI), United Kingdom
Executive Director Research, Medical & Innovation
Transparency in the U.K. & Brexit
Amanda Hunn, MA
AJ Hunn Associates, United Kingdom
Self-employed Advisor/Formerly Head of Policy and Public Affairs At the HRA